Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB5121 in relapsed or refractory CNS lymphoma
NL-OMON53713Phase 2Withdrawn
- Sponsor
- Gossamer Bio
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GB5121 in primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL) and vitreoretinal lymphoma (PVRL) (3 arms), sponsored by Gossamer Bio. Primary endpoints: Incidence of adverse events, dose-limiting toxicities, and serious adverse events, Optimal biological dose, maximum tolerated dose, and recommended phase 2 dose and 2 more. Planned start Oct 2022; status: withdrawn.
02
Drugs
GB5121
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)vitreoretinal lymphoma (PVRL)
Beyond the preview
Go deeper on NL-OMON53713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53713.